Isavuconazole: A New Option for the Management of Invasive Fungal Infections

Annals of Pharmacotherapy

Volumn 49, Issue 7, 2015, Pages 825-842

  Pettit, Natasha N ^a   Carver, Peggy L ^b,c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

antifungal agents; aspergillosis; candidiasis; invasive fungal infections; isavuconazole; mold infections; Mucor; pharmacokinetics; triazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; ISAVUCONAZONIUM; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; NITRILE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDEMIA; CONJUNCTIVITIS; COUGHING; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; ESOPHAGUS CANDIDIASIS; HUMAN; INVASIVE CANDIDIASIS; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUCORALES; NAUSEA; NONHUMAN; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; QT PROLONGATION; SYSTEMIC MYCOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRICHOSPORON; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; CANDIDIASIS; CANDIDIASIS, INVASIVE; CLINICAL TRIAL (TOPIC);

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CANDIDIASIS, INVASIVE; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, FUNGAL; HUMANS; NITRILES; PYRIDINES; TRIAZOLES; VORICONAZOLE;

EID: 84931097019     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015581679     Document Type: Article

References (98)

1. McNeil MM,Nash SL,Hajjeh RA, et al.Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.Clin Infect Dis. 2001;33:641-647
2. Drgona L,Khachatryan A,Stephens J, et al.Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.Eur J Clin Microbiol Infect Dis. 2014;33:7-21
3. Alexander BD,Johnson MD,Pfeiffer CD, et al.Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.Clin Infect Dis. 2013;56:1724-1732
4. Lewis RE.Current concepts in antifungal pharmacology.Mayo Clin Proc. 2011;86:805-817
5. Larru B,Zaoutis TE.Newer antifungal agents.Curr Opin Pediatr. 2013;25:110-115
6. Schmitt-Hoffmann A,Roos B,Heep M, et al.Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.Antimicrob Agents Chemother. 2006;50:279-285
7. Ohwada J,Tsukazaki M,Hayase T, et al.Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole.Bioorg Med Chem Lett. 2003;13:191-196
8. Ghannoum MA,Rice LB.Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.Clin Microbiol Rev. 1999;12:501-517
9. Groll AH,Kolve H.Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.Eur J Clin Microbiol Infect Dis. 2004;23:256-270
10. Eschenauer GA,Carver PL.The evolving role of antifungal susceptibility testing.Pharmacotherapy. 2013;33:465-475
11. Perkhofer S,Lechner V,Lass-Florl C.In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.Antimicrob Agents Chemother. 2009;53:1645-1647
12. Warn PA,Sharp A,Denning DW.In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.J Antimicrob Chemother. 2006;57:135-138
13. Espinel-Ingroff A,Chowdhary A,Gonzalez GM, et al.Isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex by the CLSI broth microdilution method (M27-A3 document): a multicenter study [published online October 15, 2014].Antimicrob Agents Chemother. 2014;:
14. Espinel-Ingroff A,Chowdhary A,Gonzalez GM, et al.Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.Antimicrob Agents Chemother. 2015;59:666-668
15. Espinel-Ingroff A,Chowdhary A,Gonzalez GM, et al.Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.Antimicrob Agents Chemother. 2013;57:3823-3828
16. Pfaller MA,Messer SA,Dietrich RR,Rhomberg PR,Jones RN,Castanheira MIsavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Opportunistic Fungi Collected in 2013: Application of New Clinical Breakpoints and Epidemiological Cutoff Values. Washington, DC: ICAAC; 2014:
17. Pfaller MA,Castanheira M,Messer SA,Rhomberg PR,Jones RN.Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.Diagn Microbiol Infect Dis. 2014;79:198-204
18. Guinea J,Pelaez T,Recio S,Torres-Narbona M,Bouza E.In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.Antimicrob Agents Chemother. 2008;52:1396-1400
19. Seifert H,Aurbach U,Stefanik D,Cornely O.In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Antimicrob Agents Chemother. 2007;51:1818-1821
20. Yamazaki T,Inagaki Y,Fujii T, et al.In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.Int J Antimicrob Agents. 2010;36:324-331
21. Pfaller MA,Messer SA,Rhomberg PR,Jones RN,Castanheira M.In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.J Clin Microbiol. 2013;51:2608-2616
22. Taj-Aldeen SJ,Kolecka A,Boesten R, et al.Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.Infection. 2014;42:393-404
23. Taj-Aldeen SJ,AbdulWahab A,Kolecka A,Deshmukh A,Meis JF,Boekhout T.Uncommon opportunistic yeast bloodstream infections from Qatar.Med Mycol. 2014;52:552-556
24. Sharma C,Wankhede S,Muralidhar S, et al.Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India.Diagn Microbiol Infect Dis. 2013;76:46-50
25. Orozco AS,Higginbotham LM,Hitchcock CA, et al.Mechanism of fluconazole resistance in Candida krusei.Antimicrob Agents Chemother. 1998;42:2645-2649
26. Martin de la Escalera C,Aller AI,Lopez-Oviedo E, et al.Activity of BAL 4815 against filamentous fungi.J Antimicrob Chemother. 2008;61:1083-1086
27. Andes D,Ghannoum M,Kovanda L, et alOutcomes by Minimum Inhibitory Concentrations from Isavuconazole Phase 3 Trial of Invasive Aspergillosis (SECURE). Washington, DC: ICAAC; 2014:
28. Shivaprakash MR,Geertsen E,Chakrabarti A,Mouton JW,Meis JF.In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.Mycoses. 2011;54:e583-e589
29. Arendrup MC,Howard S,Lass-Florl C,Mouton JW,Meletiadis J,Cuenca-Estrella M.EUCAST isavuconazole susceptibility testing of Aspergillus: comparison of results for inoculum standardisation using conidia counting versus optical density [published online August 20, 2014].Antimicrob Agents Chemother.:
30. Datta K,Rhee P,Byrnes E, et al.Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii: emerging fungal pathogens with reduced azole susceptibility.J Clin Microbiol. 2013;51:3090-3093
31. Rudramurthy SM,Chakrabarti A,Geertsen E,Mouton JW,Meis JF.In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.Diagn Microbiol Infect Dis. 2011;71:370-377
32. Illnait-Zaragozi MT,Martinez GF,Curfs-Breuker I,Fernandez CM,Boekhout T,Meis JF.In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrob Agents Chemother. 2008;52:1580-1582
33. Chowdhary A,Prakash A,Randhawa HS, et al.First environmental isolation of Cryptococcus gattii, genotype AFLP5, from India and a global review.Mycoses. 2013;56:222-228
34. Datta K,Rhee P,Byrnes E.Isavuconazole activity against emerging fungal pathogens with reduced azole-susceptibility: Aspergillus lentulus, Neosartorya udagawae and Cryptococcus gattii [published online June 28, 2013].J Clin Microbiol.:
35. Espinel-Ingroff A,Aller AI,Canton E, et al.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Antimicrob Agents Chemother. 2012;56:5898-5906
36. Espinel-Ingroff A,Chowdhary A,Cuenca-Estrella M, et al.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.Antimicrob Agents Chemother. 2012;56:3107-3113
37. Guinea J,Hagen F,Pelaez T, et al.Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain.Med Mycol. 2010;48:942-948
38. Hagen F,Illnait-Zaragozi MT,Bartlett KH, et al.In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.Antimicrob Agents Chemother. 2010;54:5139-5145
39. Hagen F,Illnait-Zaragozi MT,Meis JF, et al.Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.J Clin Microbiol. 2012;50:1918-1926
40. Illnait-Zaragozi MT,Martinez-Machin GF,Fernandez-Andreu CM, et al.Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis.BMC Infect Dis. 2010;10:
41. Thompson GR,Fothergill AW,Wiederhold NP,Vallor AC,Wickes BL,Patterson TF.Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.Antimicrob Agents Chemother. 2008;52:2959-2961
42. Thompson GR,Wiederhold NP,Fothergill AW,Vallor AC,Wickes BL,Patterson TF.Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.Antimicrob Agents Chemother. 2009;53:309-311
43. Guinea J,Recio S,Escribano P,Pelaez T,Gama B,Bouza E.In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.Antimicrob Agents Chemother. 2010;54:4012-4015
44. Taj-Aldeen SJ,Al-Ansari N,El Shafei S, et al.Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov.J Clin Microbiol. 2009;47:1791-1799
45. Thompson GR,Wiederhold NP,Sutton DA,Fothergill A,Patterson TF.In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.J Antimicrob Chemother. 2009;64:79-83
46. Verweij PE,Gonzalez GM,Wiedrhold NP, et al.In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.J Chemother. 2009;21:272-281
47. Gonzalez GM.In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.Med Mycol. 2009;47:71-76
48. Chowdhary A,Kathuria S,Singh PK, et al.Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.Mycoses. 2014;57:97-107
49. Chakrabarti A,Shivaprakash MR,Curfs-Breuker I,Baghela A,Klaassen CH,Meis JF.Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.J Clin Microbiol. 2010;48:4580-4585
50. Ervens J,Ghannoum M,Graf B,Schwartz S.Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.Infection. 2014;42:429-432
51. Lackner M,de Hoog GS,Verweij PE, et al.Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.Antimicrob Agents Chemother. 2012;56:2635-2642
52. Cornely OA,Ostrosky-Zeichner L,Rahav G, et alTreated With Isavuconazole: Experience From the VITAL and SECURE Trials. Washington, DC: ICAAC; 2014:
53. Al-Hatmi AM,van Diepeningen AD,Curfs-Breuker I,de Hoog GS,Meis JF.Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex.J Antimicrob Chemother. 2015;70:1068-1071
54. Thompson G,Rendon A,Santos R, et alOutcomes in Patients with Invasive Fungal Disease Caused by Dimorphic Fungi Treated with Isavuuconazole: Experience From the VITAL Trial. American Society for Microbiology Infectious Diseases Society of America (IDSA) 54th Annual Meeting American Society for Microbiology and Infectious Diseases Society of America. Washington, DC: ICAAC; 2014:
55. Wheat L,Connolly P,Smedema M,Durkin M,Goldman MIn Vitro Activity of a New Triazole, BAL8557, Against Histoplasma capsulatum From Patients Failing Fluconazole. Paris, France: ISHAM; 2006:
56. Badali H,de Hoog GS,Sudhadham M,Meis JF.Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist.Med Mycol. 2011;49:819-824
57. Peman J,Canton E,Espinel-Ingroff A.Antifungal drug resistance mechanisms.Expert Rev Anti Infect Ther. 2009;7:453-460
58. Lupetti A,Danesi R,Campa M,Del Tacca M,Kelly S.Molecular basis of resistance to azole antifungals.Trends Mol Med. 2002;8:76-81
59. Sanglard D,Ischer F,Coste A,Ferrari SComparison Between Isavuconazole and Other Azoles Against Characterised Clinical Isolates and Yeast Model Systems. Barcelona, Spain: ECCMID; 2008:
60. Diaz-Guerra TM,Mellado E,Cuenca-Estrella M,Rodriguez-Tudela JL.A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus.Antimicrob Agents Chemother. 2003;47:1120-1124
61. Chamilos G,Kontoyiannis DP.Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.Drug Resist Updat. 2005;8:344-358
62. Mellado E,Garcia-Effron G,Alcazar-Fuoli L,Cuenca-Estrella M,Rodriguez-Tudela JL.Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs.Antimicrob Agents Chemother. 2004;48:2747-2750
63. Mellado E,Garcia-Effron G,Alcazar-Fuoli L, et al.A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.; 2007; 2007. 1897.
64. Chowdhary A,Kathuria S,Randhawa HS,Gaur SN,Klaassen CH,Meis JF.Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India.J Antimicrob Chemother. 2012;67:362-366
65. Rajendran R,Mowat E,McCulloch E, et al.Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity.Antimicrob Agents Chemother. 2011;55:2092-2097
66. Lepak AJ,Marchillo K,Vanhecker J,Andes DR.Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.Antimicrob Agents Chemother. 2013;57:6284-6289
67. Lepak AJ,Marchillo K,Vanhecker J,Diekema D,Andes DR.Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Antimicrob Agents Chemother. 2013;57:5642-5648
68. Salas V,Pastor FJ,Calvo E,Sutton DA,Fothergill AW,Guarro J.Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.Antimicrob Agents Chemother. 2013;57:1404-1408
69. te Dorsthorst DTA,Verweij PE,Meis JFGM,Mouton JWPharmacodynamics of BAL4815, a New Azole Antifungal in a Mouse Model of Systemic Infection. Washington, DC: ICAAC; 2004:
70. Warn PA,Sharp A,Majithiya JB,Parmar A,Denning DW.In vitro post antibiotic effect of isavuconazole, voriconazole and amphotericin against a strain of C. albicans with concentration dependent pharmacokinetics in a murine model and susceptibility of strains from mouse kidneys post infection.Paper presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases, ECCMID; 2008Barcelona, Spain; 2008.
71. Warn PA,Sharp A,Parmar A,Majithiya J,Denning DW,Hope WW.Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.Antimicrob Agents Chemother. 2009;53:3453-3461
72. Schmitt-Hoffmann A,Roos B,Maares J, et al.Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.Antimicrob Agents Chemother. 2006;50:286-293
73. Schmitt-Hoffmann A,Roos B,Spickermann J, et al.Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.Antimicrob Agents Chemother. 2009;53:4885-4890
74. Knoll BM.Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery.J Antimicrob Chemother. 2014;69:3441-3443
75. Cornely OA,Bohme A,Schmitt-Hoffmann A,Ullmann AJ.Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.Antimicrob Agents Chemother. 2015;59:2078-2085
76. Advisory Committee Briefing Document. Isavuconazonium: invasive aspergillosis and invasive mucormycosis. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM430748.pdf. Accessed March 29, 2015.
77. Desai A,Kovanda L,Kowalski D,Lu Q,Townsend RIsavuconazole (ISA) Population Pharmacokinetic Modeling From Phase 1 and Phase 3 Clinical Trials and Target Attainment Analysis. Washington, DC: ICAAC; 2014:
78. Schmitt-Hoffmann A,Roos B,Roerhle M, et al.No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data.; 2008Paper presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology; 2008.
79. Schmitt-Hoffmann A,Roos B,Roerhle M, et alNo Relevant Food Effect in Man on Isavuconazole Oral Pharmacokinetics: Preliminary Data. ICAAC American Society for Microbiology -Infectious Diseases Society of America (IDSA) 46th Annual Meeting American Society for Microbiology and Infectious Diseases Society of America. Washington, DC: ICAAC; 2008:
80. Marr KA,Bow E,Heinz W, et alA Phase 3 Randomized, Double-Blind, Non-Inferiority Trial Evaluating Isavuconazole (ISA) vs Voriconazole (VRC) for the Primary Treatment of Invasive Mold Infection (SECURE): Outcomes in Subset of Patients with Hematologic Malignancies (HM). Washington, DC: ICAAC; 2014:
81. Ullmann AJ,Shoham S,Huang W,Mujais SA Phase 3 Randomized, Double-Blind, Non-Inferiority Trial Evaluating Isavuconazole (ISA) vs Voriconazole (VRC) for the Primary Treatment of Invasive Fungal Disease (IFD) Caused by Aspergillus spp. or other Filamentous Fungi (SECURE): Outcomes by Malignancy Status. Washington, DC: ICAAC; 2014:
82. Ruping MJ,Albermann N,Ebinger F, et al.Posaconazole concentrations in the central nervous system.J Antimicrob Chemother. 2008;62:1468-1470
83. FDA briefing document: Anti-infective Drugs Advisory Committee Meeting January 22, 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM430747.pdf. Accessed March 29, 2015.
84. Saad AH,DePestel DD,Carver PL.Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.Pharmacotherapy. 2006;26:1730-1744
85. Surowiec D,DePestel DD,Carver PL.Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management.Pharmacotherapy. 2008;28:719-729
86. Majithiya J,Sharp A,Parmar A,Denning DW,Warn PA.Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.J Antimicrob Chemother. 2009;63:161-166
87. Warn PA,Sharp A,Denning DDose Response Curves and Dose Fractionation Studies with BAL8557 in a Murine Model of Disseminated Aspergillosis. Washington, DC: ICAAC; 2006:
88. Luo G,Gebremariam T,Lee H,Edwards JE,Kovanda L,Ibrahim AS.Isavuconazole therapy protects immunosuppressed mice from mucormycosis.Antimicrob Agents Chemother. 2014;58:2450-2453
89. Gagne LS,Hammond SP,Gilmore ET,Joyce AC,Soiffer RJ,Marty FMIsavuconazole Treatment of Disseminated Zycomycosis. Boston, MA: IDSA; 2011:
90. Prakash A,Wankhede S,Singh PK, et al.First neonatal case of fungaemia due to Pseudozyma aphidis and a global literature review.Mycoses. 2014;57:64-68
91. Peixoto D,Gagne LS,Hammond SP, et al.Isavuconazole treatment of a patient with disseminated mucormycosis.J Clin Microbiol. 2014;52:1016-1019
92. Viljoen J,Azie N,Schmitt-Hoffmann AH,Ghannoum M.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.Antimicrob Agents Chemother. 2015;59:1671-1679
93. Astellas Pharma Inc. Isavuconazole (BAL8557) in the treatment of candidemia and other invasive candida infections. http://clinicaltrials.gov/ct2/show/NCT00413218?term=NCT00444366&rank=1. Accessed March 29, 2015.
94. Basilea Pharmaceutica. Press release. http://www.basilea.com/News-and-Media/Basilea-and-Astellas-update-isavuconazole-phase-III-trial-in-consultation-with-FDA/385. Accessed March 29, 2015.
95. Queiroz-Torres F,Cornely O,Perfect J,Kovanda L,Zeiher B,Vazquez JSuccessful Outcomes in Patients With Invasive Fungal Disease Due to C. gattii and C. neoformans Treated With Isavuconazole: Experience From the VITAL Trial. Washington, DC: ICAAC; 2014:
96. Astellas Pharma Inc. Isavuconazole in the treatment of renally impaired aspergillosis and rare fungi. http://clinicaltrials.gov/ct2/show/NCT00634049?term=NCT00634049&rank=1. Accessed March 29, 2015.
97. Andes D.Optimizing antifungal choice and administration.Curr Med Res Opin. 2013;29:13-18
98. Pan W,Khayhan K,Hagen F, et al.Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes.PLoS One. 2012;7:e32868